403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
JFDA Confirms Safety, Quality Of Ozempic Batches In Local Market
(MENAFN- Jordan News Agency)
Amman, June 26 (Petra) - The Jordan Food and Drug Administration (JFDA) has confirmed that the batches of the "Semaglutide" preparation, branded as "Ozempic," available in the local market are approved and have successfully undergone rigorous laboratory procedures and tests, ensuring their quality, safety, and effectiveness.
Nizar Mhaidat, Director-General of the Administration, stated that the counterfeit formulations mentioned in a recent World Health Organization alert were not distributed in the Jordanian market.
He emphasized that the legally approved concentrations of the preparation, 0.25 mg, 0.5 mg, and 1 mg, are registered for the treatment of diabetes. However, its use for treating obesity and weight loss is not approved, and no clinical studies have been provided to support such usage.
Mhaidat highlighted that the JFDA continually emphasizes to relevant health authorities the importance of adhering to the approved indications for prescribing and dispensing the preparation. This ensures patient safety and the continued availability of medication for diabetic patients.
As a precautionary measure, the JFDA, in coordination with the manufacturer, has adopted a guide to educate patients and healthcare providers on distinguishing the original product from counterfeit versions.
For comments, inquiries, or complaints, the JFDA can be contacted via the toll-free complaints line at 117114, email at ..., or WhatsApp at (0795632000).
Amman, June 26 (Petra) - The Jordan Food and Drug Administration (JFDA) has confirmed that the batches of the "Semaglutide" preparation, branded as "Ozempic," available in the local market are approved and have successfully undergone rigorous laboratory procedures and tests, ensuring their quality, safety, and effectiveness.
Nizar Mhaidat, Director-General of the Administration, stated that the counterfeit formulations mentioned in a recent World Health Organization alert were not distributed in the Jordanian market.
He emphasized that the legally approved concentrations of the preparation, 0.25 mg, 0.5 mg, and 1 mg, are registered for the treatment of diabetes. However, its use for treating obesity and weight loss is not approved, and no clinical studies have been provided to support such usage.
Mhaidat highlighted that the JFDA continually emphasizes to relevant health authorities the importance of adhering to the approved indications for prescribing and dispensing the preparation. This ensures patient safety and the continued availability of medication for diabetic patients.
As a precautionary measure, the JFDA, in coordination with the manufacturer, has adopted a guide to educate patients and healthcare providers on distinguishing the original product from counterfeit versions.
For comments, inquiries, or complaints, the JFDA can be contacted via the toll-free complaints line at 117114, email at ..., or WhatsApp at (0795632000).
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment